Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rebonuputemcel,Inapplicable
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
DiscGenics Gets FDA Nod for Phase III Trial of Injectable Disc Progenitor Cells
Details : Rebonuputemcel is an allogeneic, injectable disc progenitor cell therapy, is under investgaten for painful lumbar degenerative disc disease.
Product Name : IDCT
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 16, 2024
Lead Product(s) : Rebonuputemcel,Inapplicable
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rebonuputemcel,Inapplicable
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : High dose IDCT (Allogeneic Discogenic Progenitor Cell Therapy) also produced clinically meaningful, statistically significant improvements in function and quality of life by 12 weeks following intradiscal injection with durability sustained at the one-ye...
Product Name : IDCT
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : Rebonuputemcel,Inapplicable
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rebonuputemcel,Inapplicable
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This prospective, randomized, double-blinded, sham-controlled, multicenter clinical study is designed to evaluate the safety and preliminary efficacy of IDCT in patients with symptomatic, single-level, mild to moderate lumbar disc degeneration.
Product Name : IDCT
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 27, 2021
Lead Product(s) : Rebonuputemcel,Inapplicable
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Discogenic Cell,Sodium Hyaluronate
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 20, 2019
Lead Product(s) : Discogenic Cell,Sodium Hyaluronate
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Discogenic Cell,Sodium Hyaluronate
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I
Sponsor : CTI Clinical Trial and Consulting
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 20, 2017
Lead Product(s) : Discogenic Cell,Sodium Hyaluronate
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I
Sponsor : CTI Clinical Trial and Consulting
Deal Size : Inapplicable
Deal Type : Inapplicable